What is the role of tyrosine kinase inhibitors in the treatment of glioblastoma multiforme (GBM)?

Updated: Jul 28, 2021
  • Author: Jeffrey N Bruce, MD; Chief Editor: Herbert H Engelhard, III, MD, PhD, FACS, FAANS  more...
  • Print
Answer

A small proportion of glioblastomas responds to gefitinib or erlotinib (tyrosine kinase inhibitors). The simultaneous presence in glioblastoma cells of mutant EGFR (EGFRviii) and PTEN was associated with responsiveness to tyrosine kinase inhibitors, whereas increased p-akt predicts a decreased effect. [119, 120, 121] Other targets include PDGFR, VEGFR, mTOR, farnesyltransferase, and PI3K.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!